[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 69, "title": "CEO, President & Executive Director", "yearBorn": 1956, "fiscalYear": 2025, "totalPay": 1139142, "exercisedValue": 0, "unexercisedValue": 110613328}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 71, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2025, "totalPay": 808143, "exercisedValue": 3196231, "unexercisedValue": 60712612}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2025, "totalPay": 770393, "exercisedValue": 827723, "unexercisedValue": 10852775}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 52, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2025, "totalPay": 790051, "exercisedValue": 11558026, "unexercisedValue": 12724696}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 49, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2025, "totalPay": 695419, "exercisedValue": 9576082, "unexercisedValue": 7423517}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 38, "title": "Chief Strategy & Business Officer", "yearBorn": 1987, "fiscalYear": 2025, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 58, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 34.63, "open": 34.5, "dayLow": 34.0, "dayHigh": 36.0, "regularMarketPreviousClose": 34.63, "regularMarketOpen": 34.5, "regularMarketDayLow": 34.0, "regularMarketDayHigh": 36.0, "payoutRatio": 0.0, "beta": 0.069, "forwardPE": -26.400434, "volume": 765190, "regularMarketVolume": 765190, "averageVolume": 834326, "averageVolume10days": 659090, "averageDailyVolume10Day": 659090, "bid": 35.38, "ask": 35.73, "bidSize": 1, "askSize": 1, "marketCap": 4034444800, "fiftyTwoWeekLow": 14.06, "fiftyTwoWeekHigh": 42.0, "allTimeHigh": 42.0, "allTimeLow": 5.633, "priceToSalesTrailing12Months": 179.28476, "fiftyDayAverage": 34.1276, "twoHundredDayAverage": 28.2996, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3454786560, "profitMargins": 0.0, "floatShares": 69227851, "sharesOutstanding": 113390804, "sharesShort": 7100900, "sharesShortPriorMonth": 6213363, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0626, "heldPercentInsiders": 0.00461, "heldPercentInstitutions": 1.06234, "shortRatio": 9.89, "shortPercentOfFloat": 0.0746, "impliedSharesOutstanding": 113390804, "bookValue": 5.974, "priceToBook": 5.9558086, "lastFiscalYearEnd": 1767139200, "nextFiscalYearEnd": 1798675200, "mostRecentQuarter": 1767139200, "netIncomeToCommon": -203819008, "trailingEps": -2.04, "forwardEps": -1.3477051, "enterpriseToRevenue": 153.526, "enterpriseToEbitda": -15.323, "52WeekChange": 0.7280439, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 35.58, "targetHighPrice": 59.78786, "targetLowPrice": 38.062466, "targetMeanPrice": 48.72417, "targetMedianPrice": 47.875076, "recommendationMean": 1.30769, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 13, "totalCash": 636241024, "totalCashPerShare": 5.534, "ebitda": -225463008, "totalDebt": 202000, "quickRatio": 7.686, "currentRatio": 7.876, "totalRevenue": 22503000, "debtToEquity": 0.03, "revenuePerShare": 0.19, "returnOnAssets": -0.17266001, "returnOnEquity": -0.2829, "grossProfits": 22503000, "freeCashflow": -112909872, "operatingCashflow": -147783008, "revenueGrowth": -0.998, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -2061.875, "financialCurrency": "USD", "symbol": "NAMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1771625376, "regularMarketTime": 1771621200, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.74329, "regularMarketPrice": 35.58, "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "earningsTimestamp": 1771421400, "earningsTimestampStart": 1778160600, "earningsTimestampEnd": 1778160600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.04, "epsForward": -1.3477051, "epsCurrentYear": -1.69808, "priceEpsCurrentYear": -20.953077, "fiftyDayAverageChange": 1.4524002, "fiftyDayAverageChangePercent": 0.042557932, "twoHundredDayAverageChange": 7.280401, "twoHundredDayAverageChangePercent": 0.25726163, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "averageAnalystRating": "1.3 - Strong Buy", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "postMarketChangePercent": 0.0, "postMarketPrice": 35.58, "postMarketChange": 0.0, "regularMarketChange": 0.950001, "regularMarketDayRange": "34.0 - 36.0", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 834326, "fiftyTwoWeekLowChange": 21.52, "fiftyTwoWeekLowChangePercent": 1.5305831, "fiftyTwoWeekRange": "14.06 - 42.0", "fiftyTwoWeekHighChange": -6.419998, "fiftyTwoWeekHighChangePercent": -0.1528571, "fiftyTwoWeekChangePercent": 72.80439, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]